Fabino Enterprises Limited (BOM:543444)
India · Delayed Price · Currency is INR 20.31
+0.96 (4.96%)
At close: Apr 27, 2026
Fabino Enterprises Revenue
In the fiscal year ending March 31, 2026, Fabino Enterprises had annual revenue of 208.42M INR with 15.44% growth. Fabino Enterprises had revenue of 142.09M in the half year ending March 31, 2026, with 72.82% growth.
Revenue
208.42M
Revenue Growth
+15.44%
P/S Ratio
0.20
Revenue / Employee
69.47M
Employees
3
Market Cap
42.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 208.42M | 27.88M | 15.44% |
| Mar 31, 2025 | 180.54M | -30.29M | -14.37% |
| Mar 31, 2024 | 210.83M | 177.22M | 527.34% |
| Mar 31, 2023 | 33.61M | -8.40M | -20.00% |
| Mar 31, 2022 | 42.01M | 11.43M | 37.39% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivanza Biosciences | 1.17B |
| Beryl Drugs | 213.23M |
| Brawn Biotech | 172.59M |
| Unjha Formulations | 152.79M |
| Decipher Labs | 138.51M |
| Ganga Pharmaceuticals | 28.28M |
| Emmessar Biotech & Nutrition | 23.78M |
| Cresanto Global | 539.00K |